|Updated: 7/02/2012 4:05 pm
||Published: 7/02/2012 4:04 pm
LITTLE ROCK, AR – The Arkansas State Medicaid program is set to receive $7.65 million as a result of a settlement between GlaxoSmithKline, the states, and the federal government.
GSK will pay $3 billion to resolve allegations that they engaged in illegal marketing and pricing practices related to certain drugs it manufactures, according to the Arkansas Attorney General’s office. $2 billion of the settlement will go to the states and the federal government for damages and civil penalties, $1 billion will be paid in connection with federal criminal charges related to drug labeling and FDA reporting.
Arkansas’s Medicaid program will receive $2.065 million. With federal matching funds added, $7,654,782.22 will go to Arkansas Medicaid.